Ticagrelor and platelet reactivity in acute coronary syndromes
Phase 4
- Conditions
- Acute Coronary SyndromeCardiovascular - Coronary heart disease
- Registration Number
- ACTRN12613001208796
- Lead Sponsor
- Peter Larsen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Acute coronary syndrome
Exclusion Criteria
Known platelet function disorder
Platelet count less than 100
Prior administration of a P2Y12 receptor antagonist within 2 weeks
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method evel of platelet inhibition measured using platelet impedance aggregometry at 2 hours (using Multiplate system).[2 hours after loading dose]
- Secondary Outcome Measures
Name Time Method evel of platelet inhibition measured using platelet impedance aggregometry at 1, 4 and 8 hours (using Multiplate system).[at 1 hour, 4 hours and 8 hours after loading dose]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does ticagrelor utilize to inhibit platelet reactivity in acute coronary syndrome patients?
How does ticagrelor's platelet inhibition compare to clopidogrel in acute coronary syndrome management?
Which biomarkers correlate with ticagrelor response variability in acute coronary syndrome patients?
What adverse events are associated with ticagrelor loading doses in coronary heart disease patients?
Are there combination therapies involving ticagrelor that enhance platelet inhibition in acute coronary syndromes?